Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!-Reference-Cited by-同舟云学术

Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!

Published:2022-07 Issue:7 Volume:18 Page:479-487
ISSN:2688-1527
Container-title:JCO Oncology Practice
language:en
Short-container-title:JCO Oncology Practice

Author:

DuVall Adam S.¹^ORCID,Sheade Jori²,Anderson Daniela²^ORCID,Yates Samuel J.²^ORCID,Stock Wendy¹^ORCID

Affiliation:

1. University of Chicago Biological Sciences Division, Department of Medicine, Section of Hematology Oncology, Chicago, IL

2. University of Chicago Biological Sciences Division, Department of Medicine, Chicago, IL

Abstract

The treatment of acute lymphoblastic leukemia (ALL) has dramatically changed over the past three decades. However, relapsed and/or refractory ALL still remains with a very low survival and high morbidity associated with its treatment. Here, we will review the outstanding progress that has been made in the treatment of relapsed and/or refractory ALL and discuss future directions and challenges that require further investigation.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Oncology (nursing),Health Policy,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/OP.21.00843

Reference66 articles.

1. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007

2. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

3. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

4. Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies

5. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol;eJHaem;2024-08-08

2. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions;Cancer;2024-08-02

3. High expression of SLC27A2 predicts unfavorable prognosis and promotes inhibitory immune infiltration in acute lymphoblastic leukemia;Translational Oncology;2024-07

4. Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation;Transplantation and Cellular Therapy;2024-05

5. A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy;British Journal of Haematology;2024-04-13